Literature DB >> 6195192

Tissue content of dihydrotestosterone in human prostatic hyperplasis is not supranormal.

P C Walsh, G M Hutchins, L L Ewing.   

Abstract

The dihydrotestosterone content of normal peripheral and benign hyperplastic prostates was measured in tissue obtained at open surgical procedures on 29 men of ages 36 to 82 yr. The dihydrotestosterone content in normal prostates (mean +/- SE, 5.1 +/- 0.4 ng/g tissue) and in benign hyperplastic prostates (5.0 +/- 0.4) was similar. In 11 patients in whom both normal and hyperplastic prostatic tissue was harvested simultaneously at the same operation, there was no significant difference in the content of dihydrotestosterone in the two types of tissue. These findings fail to confirm the widespread belief that dihydrotestosterone content is elevated in benign hyperplastic prostates. Our data differ from the reported literature in one major respect: the dihydrotestosterone content of normal peripheral prostate in this study is three to four times higher than previously reported. This difference between the present and earlier studies was resolved by experiments performed on cadavers, which were the source of normal prostatic tissue used by other investigators. Dihydrotestosterone content was measured in seven cadavers ranging in age from 19 to 82 yr of age. The results of this experiment indicate that the dihydrotestosterone content of prostatic tissue removed at autopsy is factitiously low (0.7-1.0 ng/g tissue). This finding was confirmed by in vitro incubations of fresh prostatic tissue at 37 degrees C that demonstrated reduction of dihydrotestosterone content to low levels within 2 h. When taken together, these results indicate that when prostatic tissue is harvested appropriately, the dihydrotestosterone content of normal peripheral and hyperplastic tissues is the same. This finding should influence future research into the etiology of benign prostatic hyperplasia.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6195192      PMCID: PMC370466          DOI: 10.1172/JCI111137

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  16 in total

1.  Collection of postmortem prostate tissue under sterile conditions.

Authors:  T I Malinin
Journal:  Cancer Chemother Rep       Date:  1975 Jan-Feb

2.  A study of the conditions and mechanism of the diphenylamine reaction for the colorimetric estimation of deoxyribonucleic acid.

Authors:  K BURTON
Journal:  Biochem J       Date:  1956-02       Impact factor: 3.857

3.  Prostate concentrations of endogenous androgens by radioimmunoassay.

Authors:  J Albert; J Geller; S Geller; D Lopez
Journal:  J Steroid Biochem       Date:  1976-04       Impact factor: 4.292

4.  The conversion of testosterone to 5-alpha-androstan-17-beta-ol-3-one by rat prostate in vivo and in vitro.

Authors:  N Bruchovsky; J D Wilson
Journal:  J Biol Chem       Date:  1968-04-25       Impact factor: 5.157

5.  Selective retention of dihydrotestosterone by prostatic nuclei.

Authors:  K M Anderson; S Liao
Journal:  Nature       Date:  1968-07-20       Impact factor: 49.962

Review 6.  The intranuclear metabolism of testosterone in the accessory organs of reproduction.

Authors:  J D Wilson; R E Gloyna
Journal:  Recent Prog Horm Res       Date:  1970

7.  Dihydrotestosterone in prostatic hypertrophy. II. The formation and content of dihydrotestosterone in the hypertrophic canine prostate and the effect of dihydrotestosterone on prostate growth in the dog.

Authors:  R E Gloyna; P K Siiteri; J D Wilson
Journal:  J Clin Invest       Date:  1970-09       Impact factor: 14.808

8.  Dihydrotestosterone in prostatic hypertrophy. I. The formation and content of dihydrotestosterone in the hypertrophic prostate of man.

Authors:  P K Siiteri; J D Wilson
Journal:  J Clin Invest       Date:  1970-09       Impact factor: 14.808

9.  Comparison of androgen metabolites in benign prostatic hypertrophy (BPH) and normal prostate.

Authors:  J Geller; J Albert; D Lopez; S Geller; G Niwayama
Journal:  J Clin Endocrinol Metab       Date:  1976-09       Impact factor: 5.958

10.  Endogenous steroid levels in the human prostate from birth to old age: a comparison of normal and diseased tissues.

Authors:  G L Hammond
Journal:  J Endocrinol       Date:  1978-07       Impact factor: 4.286

View more
  21 in total

Review 1.  Review of current and future approaches to the management of benign prostatic hyperplasia.

Authors:  J C Gingell
Journal:  Postgrad Med J       Date:  1992-09       Impact factor: 2.401

2.  Circadian genes and risk of prostate cancer in the prostate cancer prevention trial.

Authors:  Lisa W Chu; Cathee Till; Baiyu Yang; Catherine M Tangen; Phyllis J Goodman; Kai Yu; Yong Zhu; Summer Han; Ashraful M Hoque; Christine Ambrosone; Ian Thompson; Robin Leach; Ann W Hsing
Journal:  Mol Carcinog       Date:  2018-01-12       Impact factor: 4.784

3.  Serum Testosterone, 17β-Estradiol and PSA Levels in Subjects with Prostate Disorders.

Authors:  Anthony J Usoro; Aniebietabasi S Obot; Itemobong S Ekaidem; Okon E Akaiso; Alphonsus E Udoh; O Akinloye
Journal:  Indian J Clin Biochem       Date:  2014-01-29

4.  Tissue distribution and ontogeny of steroid 5 alpha-reductase isozyme expression.

Authors:  A E Thigpen; R I Silver; J M Guileyardo; M L Casey; J D McConnell; D W Russell
Journal:  J Clin Invest       Date:  1993-08       Impact factor: 14.808

Review 5.  Androgens and estrogens in benign prostatic hyperplasia: past, present and future.

Authors:  Tristan M Nicholson; William A Ricke
Journal:  Differentiation       Date:  2011-05-26       Impact factor: 3.880

6.  Intranuclear androgen and cytosolic receptor concentrations in the axillary skin of osmidrosis.

Authors:  S Kurata; S Itami; S Komada; S Takayasu
Journal:  Arch Dermatol Res       Date:  1990       Impact factor: 3.017

Review 7.  Serenoa repens (Permixon). A review of its pharmacology and therapeutic efficacy in benign prostatic hyperplasia.

Authors:  G L Plosker; R N Brogden
Journal:  Drugs Aging       Date:  1996-11       Impact factor: 3.923

Review 8.  PPARγ: a molecular link between systemic metabolic disease and benign prostate hyperplasia.

Authors:  Ming Jiang; Douglas W Strand; Omar E Franco; Peter E Clark; Simon W Hayward
Journal:  Differentiation       Date:  2011-06-08       Impact factor: 3.880

Review 9.  Estrogen and androgen signaling in the pathogenesis of BPH.

Authors:  Clement K M Ho; Fouad K Habib
Journal:  Nat Rev Urol       Date:  2011-01       Impact factor: 14.432

10.  Challenges with luteinizing hormone-releasing hormone agonists: flare and surge.

Authors:  Michael K Brawer
Journal:  Rev Urol       Date:  2004
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.